nach oben

Drugs & Therapy Perspectives

Erschienen in:

01.07.2023 | Adis Drug Q&A

Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use

verfasst von: Simon Fung, Matt Shirley

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Oteseconazole (Vivjoa^®), an orally administered azole antifungal, is a valuable, efficacious, and well tolerated treatment option for reducing the incidence of vulvovaginal candidiasis (VVC) recurrence in females with a history of recurrent VVC (RVVC) who are not of reproductive potential. It is the first drug to be approved in the USA for this indication. In phase 3 clinical trials in patients with RVVC, oteseconazole significantly reduced the incidence of VVC recurrence compared with placebo and continued to prevent VVC recurrence for over 36 weeks after the final dose of the drug. Oteseconazole was non-inferior to fluconazole for resolving acute VVC. Additionally, it has a favorable pharmacokinetic profile, has activity against fluconazole-resistant Candida strains, and is generally well tolerated in patients with RVVC.

Nur mit Berechtigung zugänglich

Nyirjesy P, Brookhart C, Lazenby G, et al. Vulvovaginal candidiasis: a review of the evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections treatment guidelines. Clin Infect Dis. 2022;74(Suppl. 2):S162–8.CrossRefPubMed

Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.CrossRefPubMed

US Food and Drug Administration. DIFLUCAN^® (fluconazole tablets) for oral use: US prescribing information. 2022. https://www.fda.gov/. Accessed 14 June 2023.

Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237–45.CrossRefPubMedPubMedCentral

Adis Medical Writers. Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects. Drugs Ther Perspect. 2019;36:112–5.CrossRef

Mycovia Pharmaceuticals Inc. VIVJOA^® (oteseconazole) capsules, for oral use: US prescribing information. 2022. https://www.fda.gov/. Accessed 14 June 2023.

US Food and Drug Administration. BREXAFEMME^® (ibrexafungerp tablets), for oral use. 2022. https://www.fda.gov/. Accessed 14 June 2023.

Hoy SM. Oteseconazole: first approval. Drugs. 2022;82(9):1017–23.CrossRefPubMed

Wiederhold NP. Pharmacodynamics, mechanisms of action and resistance, and spectrum of activity of new antifungal agents. J Fungi. 2022;8(857):1–20.

10.

Lv QZ, Yan L, Jiang YY. The synthesis, regulation, and functions of sterols in Candida albicans: well-known but still lots to learn. Virulence. 2016;7(6):649–59.CrossRefPubMedPubMedCentral

11.

Warrilow AG, Hull CM, Parker JE, et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014;58(12):7121–7.CrossRefPubMedPubMedCentral

12.

Garvey EP, Hoekstra WJ, Schotzinger RJ, et al. Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015;59(9):5567–73.CrossRefPubMedPubMedCentral

13.

Schell WA, Jones AM, Garvey EP, et al. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61(3):e01817-e1916.CrossRefPubMedPubMedCentral

14.

Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63(6):1–11.CrossRef

15.

Wang L, Zhang M, Guo J, et al. In vitro activities of the tetrazole VT-1161 compared with itraconazole and fluconazole against Cryptococcus and non-albicans Candida species. Mycologia. 2021;113(5):918–25.PubMed

16.

Martens MG, Maximos B, Degenhardt T, et al. Phase 3 study of the safety and efficacy of oteseconazole in treatment of recurrent vulvovaginal candidiasis and efficacy vs fluconazole in treatment of acute vulvovaginal candidiasis infections. Am J Obstet Gynecol. 2022;227(6):880.e1-11.CrossRefPubMed

17.

Sobel J, Donders G, Degenhardt T, et al. Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis. NEJM Evid. 2022;1(8):1–13.CrossRef

18.

Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1-9.CrossRefPubMed

19.

Brand SR, Sobel JD, Nyirjesy P, et al. A randomized phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2021;73(7):e1518–24.CrossRefPubMed

20.

Sobel J, Degenhardt T, Person K, et al. Long-term observations of oteseconazole efficacy against recurrent vulvovaginal candidiasis [abstract no. 45]. Am J Obstet Gynecol. 2023;228(2 Suppl):S788–9.

21.

Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. Drugs. 2019;79(8):833–53.CrossRefPubMed

22.

Rosa MI, Silva BR, Pires PS, et al. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167(2):132–6.CrossRefPubMed

23.

Monk BC, Keniya MV, Sabherwal M, et al. Azole resistance reduces susceptibility to the tetrazole antifungal VT-1161. Antimicrob Agents Chemother. 2019;63(1):1–19.CrossRef

24.

Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–92.CrossRefPubMed

25.

Gamal A, Chu S, McCormick TS, et al. Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata. Front Cell Infect Microbiol. 2021;11: 642358.CrossRefPubMedPubMedCentral

Titel: Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use
verfasst von: Simon Fung
Matt Shirley
Publikationsdatum: 01.07.2023
Verlag: Springer International Publishing
Erschienen in: Drugs & Therapy Perspectives / Ausgabe 8/2023
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI: https://doi.org/10.1007/s40267-023-01008-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Oteseconazole in recurrent vulvovaginal candidiasis: a profile of its use

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Manage androgenetic alopecia in men with established options but emerging therapies show promise

Dextromethorphan/bupropion in major depressive disorder: a profile of its use

Desidustat in anaemia in patients with chronic kidney disease: a profile of its use

Screen for drug-induced gambling disorder in vulnerable patients receiving dopaminergic drugs

Manage early morning ADHD symptoms and functional impairment with treatments that are effective from awakening